Cardiac Power Output in Heart Failure Patients
This study is looking at heart failure patients, specifically those with cardiogenic shock (when your heart can't pump enough blood to meet your body's needs). Researchers want to see if differences in how well your heart can pump blood can predict how you'll do over time. You might be given milrinone, a drug that helps the heart pump more strongly, or no drug. The study will measure changes in your heart's pumping ability using a pulmonary artery (PA) catheter (a thin tube inserted into a blood vessel to measure pressures in your heart and lungs) at several time points. To join, your heart's pumping ability (LVEF) must be 40% or less, and you must be referred for a right heart catheterization for certain reasons, such as evaluation for advanced heart failure treatments. The study aims to enroll 5 participants, but its current status is unclear.
- Study design
- This is an interventional study where participants are randomly assigned to receive either milrinone or no agent. It is designed as a prospective, observational, crossover study.
- What's involved
- You will have measurements taken using a pulmonary artery catheter at baseline and then at 6, 12, 24, 36, and 72 hours after receiving milrinone or no agent.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your advanced heart failure therapy will be measured at 2 years after the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cardiac Power Output in Cardiogenic Shock Patients
At a glance
Conditions
NCT05700617
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Chicago
Chicago, Illinoisstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Valluvan Jeevanandam, MD · PRINCIPAL_INVESTIGATOR · University of Chicago
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring mmHgBaseline and 6,12,24,36,72 Hours post-inotrope challenge.
Changes invasive hemodynamics representing myocardial reserve will be measured in 5 patients using a pulmonary artery (PA) catheter: Pulmonary capillary wedge pressure (PCWP mmHg); Right Atrial pressure (RA mmHg); Pulmonary Atrial pressures (PA mmHg);
- Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring L/min/m2Baseline and 6,12,24,36,72 Hours post-inotrope challenge.
Changes invasive hemodynamics representing myocardial reserve will be measured in 5 patients using a pulmonary artery (PA) catheter: Cardiac output by Fick (CO L/min/m2); Cardiac index by Fick (CI L/min/m2).
- Advanced heart failure therapy2 years
Duration of time without need for definitive advanced heart failure therapy (LVAD, OHT) or death.
- Inotropes2 years
Duration of time on inotropes during hospitalization
- Death2 years
Cardiovascular death and/or all-cause mortality
- Cardiac output measurement using a pulmonary artery (PA) catheter measuring mmHg at 2 years2 years
Efficacy of increasing cardiac output with milrinone compared to dobutamine using changes invasive hemodynamics in 5 patients using a pulmonary artery (PA) catheter: Pulmonary capillary wedge pressure (PCWP mmHg), Right Atrial pressure (RA mmHg), Pulmonary Atrial pressures (PA mmHg),
- Cardiac output measurement using a pulmonary artery (PA) catheter measuring CO L/min/m2 at 2 years2 years
Efficacy of increasing cardiac output with milrinone compared to dobutamine using changes invasive hemodynamics in 5 patients using a pulmonary artery (PA) catheter: Cardiac output by Fick (CO L/min/m2), Cardiac index by Fick (CI L/min/m2.)